Aun CFF 12 Final

Competitor Fact File
Status as of August 2012
Competitor Fact File
Strategic Coordination Office
International Strategic Development & Strategic Coordination Office © August, 2012

B.Braun
Contents
1. Executive Summary 3
2. General Overview 5
3. HD Machines 20
4. Dialysers 24
5. Acute and Therapeutic Apheresis Products 27
6. Provider Business 28
7. Market Shares, Regional Coverage 33
8. Quality Issues and Litigations 36
9. History and News 39
Strictly Confidential For internal Use Only

International Strategic Development & Strategic Coordination Office © August, 2012 Page 2
B.Braun
1. Executive Summary:
B.Braun is a privately held company headquartered in Melsungen, Germany and owned by the Braun family.
In April 2011, Ludwig Georg Braun retired as CEO and for the first time a non-family member, Heinz-Walter
Große, took over this position. Still, the Braun family will continue to operate the company as a closed family
business. Ludwig Georg Braun’s son, Otto-Philipp Braun, joined the management board when his father
retired. He is responsible for the regions Iberian Peninsula and Latin America.
In 2011, B.Braun had a total group revenue of EUR 4.6bn and an EBITDA margin of 14.9%. Overall, profit
and income expectations were not met as sales increased only 4.2% and the EBITDA margin fell by 0.9%-
points. Consequently in the second half of 2011, cost reduction measures were implemented to limit an
increase in general, administrative, and selling expenses and improve the EBITDA margin. B.Braun’s
strategic goal is to reach EUR 6bn of revenue and an EBITDA margin of 17-18% in 2015. Latin America and
Asia are considered its major growth markets.
Avitum, the fully integrated dialysis products and provider business of B.Braun, is the smallest business
segment with 2011 revenues of EUR 501m (+5.5%) contributing 10.9% (2010: 10.7%) to total group
revenues. Further business segments in the B.Braun group are Hospital Care (47% of group revenues),
Aesculap and OPM (Out Patient Market).
According to FME’s Market and Competitor Survey 2011, the sale of new HD machines declined by 4.5% to
5,000 units. This represents a 2011 global market share of 7% and a market share decline of 0.6 percent
points. Dialyzer sales increased by 8.7% to total 6.6m which increased the market share by 0.1%-points to
3.1%.
In May 2012, two strong earthquakes in Northern Italy had an effect on B.Braun’s plant in Mirandola.
H.E.L.P. Plasmat Futura- and Diapact CRRT kits were affected. For one month production was temporarily
relocated.

B.Braun
1. Executive Summary:
B.Braun’s dialysis provider business is continuing its strong international expansion. In 2011, about 11,300
dialysis patients were treated in 185 B.Braun dialysis clinics (2010: 10,800 patients, 180 clinics). B.Braun
owns clinics in 23 countries including Europe, Asia, Africa and Latin America. In 2011, provider business was
established in Russia, Singapore and Germany. In April 2012, B.Braun entered Paraguay by acquiring the
majority shares of a distributor, forming B.Braun Medical SA Paraguay. In Q2 2012, B.Braun bought a third
clinic in Colombia, in addition to the purchase two small independent local providers.
Since 2008, two investment programs were set up for international business expansion:
The first program (2008-2011), was announced to be EUR 1.4bn large and included the expansion of
B.Braun's manufacturing capacities for dialysers to 9m units annually and HD machines to 15,000 units
annually, besides its ambition to achieve and maintain cost and market leadership in the infusion therapies
market.
In 2010, B.Braun announced a new worldwide EUR 1.6bn investment program for the period 2011- 2014
which will largely be financed from operating cash flow. It focuses on emerging and developing countries,
including the renewal of the location in Malaysia, expansion of its sites in Brazil and Argentina and the
construction of a new infusion solutions factory in Indonesia. The program also includes the construction of a
third L.I.F.E. factory (dialysis and apheresis machines, infusion pumps and infusion solutions) in Melsungen.
In April 2011, the investment amount was further increased to a total of EUR 2-2.5bn
At EDTA 2012 in Paris, B.Braun presents itself together with Lauer membrane water technology on a joint
booth for the first time after the forming of a partnership in February 2012.

B.Braun
2. General Overview:
Headquarters: Carl-Braun-Straße 1 and Pfieffewiesen Europe building,
34212 Melsungen, Germany
History: Founded in 1839
Ownership: Ludwig Georg Braun and his family
In its 2011 annual report, B.Braun reaffirmed that the company will
remain a closed family company and will not pursue a public offering
Organizational Structure:
B.Braun Melsungen AG
Out Patient Market

Hospital Care Aesculap* B.Braun Avitum
(OPM)
• Infusion therapy • Products and services for • TransCare: transferring Extracorporeal Blood Treatment
• Regional anesthesia surgical and interventional parenterally-fed patients from • Hemodialysis products
• Wound drainage/ suction procedures in operative inpatient to outpatient care • Acute Dialysis products
• IV sets and therapy products medicine • Wound & skin care • Apheresis products
(catheters, solutions) • Surgical instruments and • Outpatient IV therapy • Dialysis services
• Pharmaceuticals and products sterilization containers • Diabetic care
for drug admixture • Orthopaedics & traumatology • Stoma & incontinence care
• Pumps & associated systems • Neurosurgery • Disinfection
• Clinical nutrition • Spinal and vascular surgery • Hygiene
• Automated infusion systems • Urology
* based in Tuttlingen, Germany

B.Braun
Major Shareholdings of B.Braun Melsungen AG – Germany and Europe:
Operations in 56 countries; 196 consolidated companies; 3 minority owned joint venture companies; 18
holdings
1) Effective stake 2) Companies with profit and loss transfer agreements

3) Consolidated using equity method 4) Consolidated proportionally Source: B.Braun Annual Report 2011

B.Braun
Major Shareholdings of B.Braun Melsungen AG – Americas, Asia, Australia, Africa & other holdings
Operations in 56 countries; 196 consolidated companies; 3 minority owned joint venture companies; 18
holdings
1) Effective stake 2) Companies with profit and loss transfer agreements

3) Consolidated using equity method 4) Consolidated proportionally
Source: B.Braun Annual Report 2011

B.Braun
Executive Management – Management Board:
In March 2012, Dr.

Annette Beller and
Otto Philipp Braun
were appointed as
full board
members effective
on April 01, 2012
From left:
Otto-Philipp Dr. rer. pol. Heinz- Dr. Annette Dr. rer. nat. Meinrad Lugan Caroll H. Neubauer Prof. Dr. med. Hanns-Peter Dr. rer. nat. Wolfgang Feller
Braun Walter Große Beller • Head of Hospital Care • Chairman and CEO of Knaebel • Head of Avitum
• Responsible for • Chairman of the • Head of and OPM B.Braun Medical North America • Head of Aesculap
the regions Management Board Finance, Tax • Chairman of the board of • Prev. position: Head of Clinical
Iberian • Successor of Ludwig & Controlling B.Braun Foundation Sciences Department
Peninsula and Georg Braun • Successor of • Chairman of the board of at Aesculap with global
Latin America • Previous position: Heinz-Walter BVMed responsibility for
Head of Finance and Große marketing & sales
Human Resources

B.Braun
Executive Management – Supervisory Board: From left:
• Mike Schwarz, Member of the Work’s Council
• Rainer Heoke, Member of the Work’s Council
• Prof. Dr. Oliver Schnell, Managing Director of Sciarc GmbH,
Baierbrunn, Exec. Mamber of the Board of Forschergruppe
Diabetes e.V. at Helmholtz Zentrum
• Edeltraud Glänzer, Member of the Managing Board of IG BCE,
Hannover
• Prof. Dr. rer. pol. Thomas Rödder, Tax Advisor and Certified
Public Accountant, Partner, Flick Gocke Schaumburg, Bonn
• Barbara Braun-Lüdicke, Businesswoman, Melsungen
• Prof. Dr. med. habil. Dr. Ing. Dr. h. c. Michael Ungethüm,
former Vice Chairman of the Management Board of
B.Braun Melsungen AG
• Hans-Carsten Hansen, Predisent Human Resources, BASF SE,
Ludwigshafen
• Sonja Siewert, Member of the Work’s Council
• Dr. h.c. August Oetker, Partner, Dr. August Oetker KG
• Dr. H.C. Ludwig Georg Braun, Chairman, Former Chairman of
the Management Board of B.Braun Melsungen AG
Source: B.Braun Annual Report 2011 • Ekkehard Rist, Vice Chairman of the Work’s Council of B.Braun
Germany and Aesculap AG , Tuttlingen
• Peter Hohmann, Vice Chairman/Chairman of the Workers’
Council of B.Braun Meldungen AG, Melsungen
• Dr. Rer. Pol. Antonius Engberding, Member of the Executive
Board of IG Metall, Frankfurt/Main
• Manfred Herres, Production Director, B.Braun Avitum
• Dr. Joachim Rauhut, Member of the Managing Board of Wacker
Chemie AG, Munich

B.Braun
Key Figures:
Euro m 2007 2008 2009 2010 2011 2010/2011
%-change
Total Revenues 3,573 3,786 4,028 4,423 4,609 + 4.2
Revenues Avitum 351 403 421 475 501 + 5.5
Thereof provider ~ 130 E ~152 E ~ 160 E ~ 194 E ~ 213 E + 30.0

bus.*
R&D 116 130 139 155 180 + 16.1
Operating Profit 349 346 411 456 432 - 5.3
Cash Flow from 298 364 571 389 450 + 15.7

Operating
Activities
Cash Flow from - 357 - 467 - 443 - 557 - 548 + 1.6

Investing
Activities
Free Cash Flow - 59 - 103 176 - 168 - 98 + 41.7
Cash and Cash 41 53 49 34 45 + 32.4

Equivalents at
Year End
Employees 35,810 38,460 39,500 41,666 43,676 + 4.8
2010 Operating profit margin:11.0% 2011 Operating profit margin:9.4 %

* Incl. EuroCare, SaludCare

B.Braun
Key Figures:
Total revenues 2011: EUR 4,609m
Corporate Corporate Corporate

% Revenues % Revenues % Revenues
by Division by Business Type by Region
in 2011 in 2011 in 2011
Avitum Others Services Asia & Australia

11% Hospital Care 9%
15%
1%
OPM Europe
12%
39% & Africa
47%
NA 19%
29% 7%
Aesculap 91% LA 20%
Products Germany

B.Braun
Group Strategy:
• After the “retirement” of Ludwig Georg Braun in April 2011, continuation as closed family business
• Equity ratio of ~42 % in 2011 (target: 45%) to maintain the independence and foundation for long-term success
• Group Targtes for 2015:
• EUR 6bn revenue
• EBITDA margin of 17 – 18 percent of sales
• Global development of Avitum as fully integrated dialysis products and service provider
• Increasing centralization of functions (lean and cost-optimized organization) with divisional organization structured
in Centers of Excellence
• Organic growth through international investment programs (2007-2015) for business and manufacturing capacity
expansion, totaling ~ EUR 4.6bn (more information on pages 16-17)
• Asia and Latin America are major growth markets; Asia-Pacific region is expected to contribute more than EUR
1.2bn ~ 20% to group revenues in 2015; North America and Europe moderate growth expected
• In 2012, B.Braun became more active in India, acquiring a controlling stake in Oyster Medisafe, a medical devices
manufacturer in the state of Andhra Pradesh where B.Braun is operating a PPP since 2010; in addition it entered
into a share purchase agreement with Ahlcon Parenterals; this strengthens B.Braun’s market presence and is in line
with its strategy to become the first choice in infusion therapy in India
• With the acquisition of its previous OEM manufacturer for enteral nutrition, Nutrichem in Germany, B.Braun
underlines efforts to expand its business areas into the area of clinical and enteral nutrition
• “Sharing Expertise” as guiding principle; open innovation strategy for the creation of sustainable value

B.Braun
Avitum Strategy:
• Doubling of production capacities for polysulfone dialysers to 9m and dialysis machines to 15,000 finished
in 2011; dialysis concentrates production expansion to a capacity of 37m bags in Glandorf begun 2011,
expected completion in 2013
• Internationalization of dialysis provider business through acquisition and opening of new clinics
• Public private partnerships as means of provider expansion in India (Andhra Pradesh) and in Germany
with GTZ to train nurses in the use of modern medical equipment and products in Kenya
• India, South Africa, and Russia are considered major growth markets in provider business; growth rates
were reported as “satisfying” in these countries in 2011 (internal sources estimate B.Braun patient growth
rates to be above market growth in these three countries)
• HD business is secured through regional co-operations and agreements with other market participants
(e.g. agreement with Baxter in Eastern Europe, where 30% of all new patients in B.Braun centers are
targeted for starting on PD with Baxter equipment)

B.Braun
Key Partnerships:
• 2012, cooperation with Lauer membrane water technology; B.Braun takes over sale for Lauer’s dialysis
water technology worldwide
• LDIAMON delivers online clearance measurement tool Adimea for Dialog+
• AM2PAT manufactures pre-filled heparin and saline flush syringes under the B.Braun Medical Inc. label
• Heparin supplied by Wisconsin-based Scientific Protein Laboratories, which operates a manufacturing plant
in Changzhou, China
• Supply agreement with NxStage for the delivery of blood tubing sets by NxStage’s in-center business
Medisystems for B.Braun‘s Dialog hemodialysis systems; B.Braun provides sales, marketing and clinical
support to its customers in the US; in Jan. 2012 agreement was extended through 2014
• Distribution of B.Braun HD solutions by Renamed in Romania
• Since 2007, partnership with Nipro, which acquired exclusive distribution rights for B.Braun‘s
cardiovascular disease products (stents, PTCA catheters) in Japan

B.Braun
Product Overview:
HD products:
• Machines
• Dialysers
• Needles, catheters,
cannulas
• Bloodlines
• Concentrates
• Disinfectants
Dialog+ Xevonta & Solcart B Bloodline Systems HD Concentrates
Diacap
Dialysers
Acute dialysis, therapeutic apheresis products:

• Acute: Diacap Acute Filter, Diapact CRRT bloodline kits,
Haemocat Signo double lumen catheter, Duosol solution
• Apheresis: Plasmafilter, Precipitatefilter, Heparinadsorber,

Ultrafilter, Plasmat Futura bloodline kit, Sodium Chloride
solution for rinsing, and reinfusion
Diapact CRRT Plasmat Futura

B.Braun
Production Sites:

B.Braun
Initially communicated investment program: EUR 1.4bn, 2008 – 2011
• B.Braun invested EUR 1.4bn across all business areas; half of the amount invested in Germany
• "Avitum Village" Dialysis Machines and Infusion Pumps, Melsungen, Germany

Cost of construction/equipment: EUR 60 million/ EUR 15 million (~ 6% of total investment)
Initial production volume: 20,000 dialysis machines; 200,000 infusion pumps
Total area: 43,000 m2; 2,800 m2 training center
Workforce: >500 employees
Construction time: 2008 - 2011
• Dialysers and Membranes, Radeberg, Germany
Cost of construction/equipment: EUR 3 million/ EUR 5 million (<1% of total investment)
Production volume: 9 million dialysers annually
Workforce: 310 employees
Start of construction: September 2008
Construction time: 18 months
Completion of construction: April 2010
Avitum Village in Melsungen, Germany

B.Braun
Initially communicated investment program: EUR 1.6bn, 2011-2014
• B.Braun invests an additional EUR 1.6bn for the construction of new and the expansion of existing
production sites after the termination of the 2008-2011 investment program
• Production expansion in developing and emerging markets
• Renewal of the location in Malaysia
• Construction of a new factory for infusion solutions in Indonesia
• Expansion of production sites in Brazil and Argentina
• Financed from the company’s operating cash flow
• Construction of a third L.I.F.E infusion factory at Pfieffewiesen location, Melsungen, Germany
Continuous communication about investment programs:
B.Braun press release, March 2012:

“(…) A total of around 2.4 billion euros was invested between 2007 and 2011 for this reason, and a
further 2 to 2.5 billion euros is foreseen for the period from 2012 to 2015(…)”
B.Braun press release, April 2011:

The new B.Braun CEO Große announces the strategic objective to increase revenues from currently
EUR 4.4bn to EUR 6bn in 2015; investments to achieve this will add up to € 2.3bn until 2015

B.Braun
B.Braun communication after earthquakes in Northern in May 2012
Two major earthquakes struck the Emilia-Romagna region in Northern Italy within less than 10 days on May
20th and 29th. The epicenter were in in Modena and Mirandola, with magnitudes of 6.0 and 5.8 respectively,
destroying major infrastructure and various medical device manufacturing plants.
Jun. 1, B.Braun plant in Mirandola was effected by the earthquake on May 20 th; none of the 200 staff
was injured; longtime delivery problems are not expected, except for concentrates in bags
Jun. 12, Parts of the production site in Mirandola were affected by both earthquakes and by
severe aftershocks; production suspension of H.E.L.P. Plasmat Futura- and Diapact CRRT Kits; ban to enter
the production building; relocation of production to a site in the area; products affected by
delivery problems: H.E.L.P. Plasmat Futura Kits, small stock of Diapact CRRT Kits, dialysis
concentrates in bags not deliverable (alternative, concentrate in canisters from
Glandorf offered)
Jul. 9, Production is resumed at Mirandola; sterilization processes for the H.E.L.P. Plasmat
Futura kits is working; stable supply situation for both the H.E.L.P. Plasmat Futura kits and the Diapact
CRRT kits
Eye-witness
photographs
of B.Braun
productionsite Mirandola and Medolla
in Mirandola, in the region
Italy Emilia-Romana,
Italy

B.Braun
3. HD Machines:
Hemodialysis Machines:
Dialog+
• Launched 2003/2004
• Adimea online clearance measurement based on UV light absorption of “urea-like”
compounds (technology delivered by LDIAMON)
• bioLogic RR Comfort biofeedback system; automatic regulation of UFR based on
periodic blood pressure measurements during dialysis
• Nexadia data management system
• Rotatable TFT monitor
• No measurement of blood temperature and volume, hematocrit and hemoglobin
• No online HDF with single needle
• In 2011, new software and modifications to electronics and hydraulics were
introduced for compliance with ISO/IEC 60601-1 standard 3rd edition
• It is rumored that a PMCFU is currently carried out with new Dialog+ version
called “Dialog+ Evolution”

B.Braun
3. HD Machines:
Hemodialysis Machines – History:
Dialog Dialog Advanced

• Launched 1994 • Production phased out
• First dialysis • Disposables and
machine with technical services still
rotatable
touchscreen available
• Integrated biofeedback
system for blood
pressure stabilisation

B.Braun
3. HD Machines:
Hemodialysis Machines – History:
Plasmat secura
HD105 HD Secura
• First automated system for LDL

• HD105 B.Braun (1978) • First HD machine with
apheresis
• First dialysis machine with single needle cross-
• Designed for H.E.L.P.
ultrafiltration unit (UF50, 1980) over
apheresis (treatment of
hypercholesterolemia)

B.Braun
3. HD Machines:
Hemodialysis Machines – Comparison of features:
Source: Marcus Klaschka, International Marketing,

Status as of August, 2012

B.Braun
4. Dialysers:
Xevonta Hi series: High-flux
Polyethersulfone (amembris)
1.0 m²  2.3 m²
Gamma sterilization
Launched at WCN 2009
Xevonta Lo series: Low-flux

Polyethersulfone (amembris)
1.0 m²  2.3 m²
Gamma sterilization
Launched at WCN 2009
At EDTA 2012 in Paris, B.Braun

presented “xevonta lounge” on its
booth, exhibiting xevonta models
H10, H12, H15, H18, H20, H23

B.Braun
4. Dialysers:
Diacap HiFlo series: High-flux
Polysulfone-PVP blend ( Polysulfone+)
1.8 m², 2.3 m²
Gamma sterilization
Launched 2008
Diacap HI PS series: High-flux

Polysulfone-PVP blend ( Polysulfone)
1 m²  2 m²
Gamma sterilization
Diacap LO PS series: Low-flux

Polysulfone-PVP blend ( Polysulfone)
1 m²  2 m²
Gamma sterilization
Diacap Acute S, M, L: Polysulfone

0.8 m²  2 m²

B.Braun
4. Dialysers:
Membrane Source, Dialyser Production and Distribution:
Membrane Production Dialyser Production Distribution
B.Braun B.Braun B.Braun

Ascalon GmbH, Berggießhübel, Saxonia Medical GmbH,
Saxony Radeberg, Saxony
Membrane: Dialysers: Annual quantities sold:
• α-Polysulfone, amembris • Diacap 6.6m (2011)
(Polyethersulfone) • xevonta
Annual production capacity:
~ 4-5m (2008)
~ 9m (2010/2011)

B.Braun
5. Acute and Therapeutic Apheresis Products

Acute Dialysis and Apheresis Machines:
Diapact CRRT Plasmat Futura apheresis machine
• For extracorporeal elimination of
• Suitable for
LDL cholesterol in patients with
continuous, intermittent and
familial hypercholesterolemia,
plasma therapies
• Integrated plate warmer for hyperlipoproteinemia (a),
hyperfibrinogenemia, transplant
the heating of infusion and
vasculopathy
dialysate fluids
• In 2010, marketed with new
• Mobile and independent of
product feature: not requiring
water sources
• Options: Diapact Perfusor on-site water treatment system
anymore and with new interface
Interface and Diapact Data
• In 2011, introduction onto the
Interface
US market as part of H.E.L.P.
Apheresis Therapy
Diapact CRRT kits Plasmat Futura Kit

B.Braun
6. Provider Business:
Dialysis Centers 2011:
• 185 dialysis centers with 11,300 patients
• Centers in 23 countries: Germany, U.K., Spain, France, Lithuania, Finland, Croatia, Slovakia, Czech
Republic, Poland, Turkey, Romania, Russia, Hungary, South Africa, Zimbabwe, Latvia, Colombia, South
Korea, Singapore, Malaysia, India, Philippines
Source: B.Braun Company Website June 2009

B.Braun
Global Patient Distribution:
Global dialysis patients in 2011: 2,164,000 (+6.8%)
Patients B.Braun centers 2011: ~ 11,300 (+4.7%)
Thereof in EMEA: ~ 9,340
Thereof in RoW: ~ 2,000
B.Braun centers 2011: 185
14,000
RoW
12,000 11,300 Europe
10,800
10,000 9,300
8,390
Patients
8,000 7,200
5,800
6,000
5,000
4,600
4,000 3,500
2,500
2,000 1,600 1,700
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
B.Braun
Patients and Centers Regional Distribution:
11,300 B.Braun patients Q4 2011 185 Centers Q4 2011

regional distribution across 23 countries
Distribution:
24% 12% 9% 7% 7% 7% 6% 6% 4% 3% 3% 2% 2% 2% 2% 1% 1% 1% 1% <1%<1% <1% <1%
2,800 28 27
2,600 26
2,400 24 23
2,200 22
2,000 20
18
1,800 18 17
1,600 16
1,400 14
12
1,200 12 11 11 11
10 10
1,000 10
800 8 7 7
600 6
4
400 4
2 2 2 2 2 2 2
200 2 1 1 1
ZWE
ROM
ZWE
ROM
MYS
MYS
DEU
HUN
HUN
KOR
KOR
HRV
RUS
RUS
SGP
TUR
COL
FRA
CZE
FRA
CZE
ESP
SVK
ESP
SVK
POL
POL
GBR
GBR
HRV
PHL
ZAF
SGP
COL
FIN
FIN
TUR
IND
LTU
LVA
IND
LTU
LVA
ZAF
PHL
PD patients
HD patients

B.Braun
International Expansion – Clinics in 23 Countries:
RUS
DEU
Europe FIN Latin America
15
13 LVA
12
11 GBR, LTU
9 ROM
8
TUR, POL
6
5 FRA 1
HUN
COL
CZE,SVK,ESP,HRV
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2008 2009 2010 2011
Asia Pacific 5 Africa

SGP
4
IND (PPP)
3
2
MYS
2
ZWE
KOR 1
1
PHL ZAF
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2005 2006 2007 2008 2009 2010 2011

B.Braun
Global Patient Distribution:
Global dialysis patients by Global patients in company-owned

center type in 2011: centers in 2011:
2,164,000 total patients 540,000 total patients
100%
Other
21%
Company B.Braun
Baxter 2% 2%
Public 25% 4%
33% Diaverum
DaVita 27%
7%
35% FME 44%
HCO
Private
2011
Source: MCS 2011

B.Braun
7. Market Shares, Regional Coverage

Sold/installed HD Machines Market Shares and Regional Distribution:
Sold/installed machines in 2011, B.Braun sold/installed machines in 2011,

Global market shares: Regional distribution [%units]:
Total: ~70,900
B.Braun: ~5,010 (7%) LA
NA 8%
Bellco
JMS Other 12%
Toray
3%
Nipro 5% 45% EMEA
1%
6% 1%
B.Braun 35%
7%
FME AP
Gambro 10% 56% B.Braun sold/installed machines in 2011,

Regional market shares [%units]:
11%
13%
Nikkiso
9%
7% 6%
3%
Global NA EMEA AP LA

B.Braun
7. Market Shares, Regional Coverage:

Existing HD Machines Market Shares and Regional Distribution:
Existing HD machines in 2011, B.Braun existing HD machines in 2011,

Total: ~589,000
B.Braun: ~30,300 (5%) LA
NA 5%
Baxter Bellco
JMS Other 16%
B.Braun 2%
Nipro 5% 2% 1% 48% EMEA
1%
6%
Toray FME 31%
6%
AP
50%
13% B.Braun existing HD machines in 2011,

Nikkiso Regional market shares [%units]:
14% 8%
Gambro 5%
4% 4% 3%

B.Braun
7. Market Shares, Regional Coverage:

Global and Regional Dialyser Market Shares and Regional Distribution:
Dialysers sold in 2011, B.Braun dialysers sold in 2011,

Total: ~212m
B.Braun: ~6.6m (3%) LA NA
AP 3%
Bellco 3%
Other 16%
Nikkiso
Baxter 5%
2%
B.Braun
Toray 3% 3%
1%
5% FME
78%
45% EMEA
Asahi 11%
B.Braun dialysers sold in 2011,

Regional market shares [%units]:
12%
Nipro 7%
13%
Gambro 3%
1% 2%
<1%

B.Braun
8. Quality Issues and Litigations:

2006 In Mar., the FDA publishes a warning letter concerning drug preparation activities performed by
Central Admixture Pharmacy Services (CAPS), a subsidiary of B.Braun Medical Inc.
2008 In Jan., AM2PAT, which manufactures pre-filled heparin syringes under the B.Braun Medical Inc.
label, recalls B.Braun branded pre-filled heparin and saline flush syringes in the US due to
potential contamination with Serratia marcescens identified in the course of an inspection by the
FDA
In Feb./Mar., B.Braun and German BfArM inform about failures of Dialog+
machines with DF-option (dialysis fluid filter) to trigger an alarm in case of an excess of
ultrafiltration volume (negative deviation in the fluid balance of up to 1000ml) in machines
which have been produced on October 16th, 2007, or later; 9 cases had been reported so far;
cause: leakage at conductivity sensor
In Mar., B.Braun Medical begins recalling 23 finished product lots of heparin sodium
injection solutions (US and Canada) after its heparin sodium supplier Scientific Protein
Laboratories informed about a heparin-like contaminant (oversulfated chondroitin sulfate) in one lot
In Apr./Jun., recall of H.E.L.P. LDL-apheresis heparin adsorber batches due to
several cases of allergic reactions
In May, British MHRA publishes a field safety notice concerning B.Braun‘s Dialog+ HD
machine; several incidences of negative deviation in the fluid balance were reported that did not
trigger an alarm although the ultrafiltration volume was to large

B.Braun

2008 In Jul./Nov., the German BfArM and in Nov., the British MHRA publish customer information letters
concerning B.Braun‘s Diacap Ultra DF-Online filters used with Nikkiso machines; cracks
occurred in the caps of Diacap Ultra dialysis fluid filters used on Nikkiso dialysis machines, causing
balance deviations during therapy; B.Braun prohibits usage of its Diacap ultrafilters on
Nikkiso machines
In Nov., Central Admixture Pharmacy Services and its parent company, B.Braun
Medical, pay more than $ 5.5m in order to settle four death cases at Mary Washington
Hospital, Virginia; affected patients became sick after heart-bypass surgeries, some died, and
others recovered after serious illnesses; plaintiffs claimed that the drug called cardioplegia was
contaminated with bacteria; Central Admixture denied liability
In Nov., Texas Attorney General accuses pharmaceutical companies including
B.Braun of illegally misreporting their drug prices in order to increase payments out of the
state Medicaid program
2009 In Mar., it is announced that the criminal court of San Bernardo, Chile has decided not to hold an
abbreviated trial for the five B.Braun laboratory executives charged with an “attack on public health
resulting death” in the case of 14 of the 23 people, who died after taking the dietary supplement
AND Nutricomp; the measure implies that the defendants could receive harsher punishments than
they would have through an abbreviated trial, now risking up to 15 years in prison
In Jul., German BfArM publishes a customer information letter concerning B.Braun‘s
blood tubing system AV-Set Dialog; leakage was observed between the lid and the corpus of the
arterial chamber; leakage will be detected by the machine‘s alarm system

B.Braun

2009 In Nov., German BfArM publishes an urgent safety information letter of B.Braun concerning its bloodline
system for single-needle treatment (Standard AV-SN-Sets) when used with Gambro AK 100-200
machines; blood may flow backward into the infusion bag during continuous infusion in single needle
therapy mode
2010 In Jun. and Aug., British MHRA and German BfArM publish urgent field safety notices concerning B.Braun's
Online Substitution Line for Dialog 7210558 and 721055A because a leakage between the non
return valve and the connector was reported in singular cases
In Sep., German BfArM, British MHRA, French Afssaps and Italian Minestero della Salute
publish field safety notices for defined series of Safety Air Detectors (SAD) for B.Braun Avitum's
Dialog+ Haemodialysis system, Diapact CRR Apheresis system and Plasmat Futura Therapeutic
plasma exchange system; in rare cases the air detection function in the venous blood line may be
impaired
In Oct., B.Braun voluntarily recalls seven lots of heparin manufactured in 2008 by its
supplier Scientific Protein Laboratories LLC (SPL); the recall is initiated by SPL because additional testing
of retained crude heparin samples indicated a trace amount of oversulfated chondroitin sulfate (OSCS)
contaminant
2012 In Jun./Jul., British MHRA and French ANSM publish Field Safety Notice concerning B.Braun Avitum‘s
Xevonta Hi 20 hemodialyers; problems during the packaging process caused sterility problems in two
batches
In Aug., the FDA issued a Class I recall for B.Braun‘s Infusomat Space Infusion System
because potential breakage of the anti free flow clip if infusion is imporperly inserted and the door shut
by force; the recall concerns all devices distributed Nov. 6, 2008 – Dec. 29, 2011

B.Braun
9. History and News:

1839 Acquisition of the Rosen Pharmacy in Melsungen, Germany by Julius Wilhelm Braun
1969 B.Braun FRABA GmbH is founded in Cologne; the company produces machines and accessories
for HD and PD and markets blood treatment products; the name FRABA is derived from Franz
Baumgartner who developed and produced the first artificial kidney in Western Germany
1971 Transformation of the company into a stock corporation
1976 Acquisition of a controlling interest in Aesculap AG
1979 B.Braun FRABA GmbH moves headquarters to Melsungen
1979 Establishment of B.Braun of America with Burron Medical Inc., Bethlehem
1980 Establishment of a production subsidiary in Penang, Malaysia
1992 Acquisition of the Medical Products Division of Angeion Corporation (interventional
accessory devices for cardiology market) (6.2 million USD)
1994 B.Braun Melsungen AG undergoes restructuring; the extracorporeal blood treatment unit is
renamed the Medical Technology division
1996 The Medical Technology division acquires Schiwa GmbH, Glandorf, Germany for the production of
dialysis liquid concentrates
1996 The Medical Technology division acquires Renamed Medizintechnik GmbH in Bremerhaven
which supplies a major share of dialysis fluids
1997 Acquisition of McGaw Inc., California (intravenous solutions and related products), a wholly-
owned subsidiary of Ivax Corporation (320 million USD)

B.Braun

1999 Aesculap sells its 59.8% share in Aesculap Meditec (Medical laser company) for
8.8 million EUR to Deutsche-Effecten- und Wechsel Beteiligungsgesellschaft AG
2000 Sale of B.Braun Biotech International GmbH to Sartorius AG, Göttingen
Agreement with Venetec International - Venetec’s StatLock safety securement device will be
included within B.Braun’s extended-dwell catheter kits
2000 Decision to adjust business year to calendar year
2001 Collaboration with Datex-Ohmeda, a world leading supplier of anaesthesia equipment, systems
and services, and emerging leader in critical care (Hospital Care segment);
transfer of administration and management from Hong Kong to Shanghai
2002 B.Braun Medical Inc., USA, joins Global Healthcare Exchange (GHX) as a global equity
member
Cooperation agreement between B.Braun Melsungen AG and Rodleben Pharma, Germany for
the development of drug-coated stents (Aesculap segment)
Agreement between B.Braun Medical Inc. and Venetec International to address
needle stick safety
2002 B.Braun Medical Inc. contracts with Cleveland Clinic to provide Central Admixture Pharmacy
Services (CAPS)
B.Braun Medical Inc. acquires a license to develop and market Vyteris Inc.’s
transdermal Lodocaine system for dermal anesthesia

B.Braun

2003 Merger of B.Braun Medizintechnologie GmbH, Melsungen, and B.Braun Schiwa GmbH & Co.
KG, Glandorf; the two companies work in the field of extracorporeal blood treatment and form a
legal entity operating under the name of B.Braun Medizintechnologie GmbH (Medtech)
Avitum, the dialysis service provider subsidiary of B.Braun Melsungen, acquires
dialysis centers from RTS (Renal Treatment Services), a subsidiary of Baxter
International (incl. centers in the Czech Republic and Slovakia)
Reports of cooperation between B.Braun and Baxter in some Eastern
Countries (e.g. Braun PD patients on Baxter products)
B.Braun Medical Inc. is selected by an American nationwide alliance of over 1,500
hospitals and health systems (Premier) for a full-line, dual-source infusion contract
B.Braun Medizintechnik GmbH wins the innovation award for its data management system
Nexadia at the first Cologne Home Haemodialysis congress
2004 Completion of acquisition of Saxonia
Continued acquisition of dialysis centers including centers in France from Baxter
and in Spain
2005 Dr. Heinz-Walter Große joins the Management Board with responsibility for Finance,
Taxes and Controlling
B.Braun acquires all shares of Ascalon GmbH
2006 B.Braun adds MAKY Dialyzer Reprocessing System to its hemodialysis product
line; B.Braun in partnership with HDC Medical will be the distributor for MAKY

B.Braun

2006 B.Braun invests 22 million Euro into its production plants Radeberg (Saxonia), which
produces dialysers, and Berggießhübel (Ascalon), which produces hollow fibers;
it is a part of a EUR 1bn investment program, which B.Braun plans for the next 3 years
B.Braun Medical Chile inaugurates a new production plant for enteral nutrition
B.Braun adds liquid nutrition products for dialysis patients to its portfolio
B.Braun opens a pharmaceutical development center; main focus of product
development will be on iv solutions for clinical nutrition such as lipid emulsions
and for anesthesia and intensive care medicine
2007 B.Braun acquires Baxter's seven renal therapy service centers in the U.K. with
more than 500 patients
B.Braun Melsungen AG announces that it will expand production capacities for its Avitum division at
the Melsungen location; production expansion is carried out in response to a large increase in the
demand for infusion and syringe pumps for the Hospital Care division, as well as for dialysis
monitors
B.Braun closes plant in Puerto Rico where it manufactured the Horizon Outlook(r) IV Safety
Infusion System and the SAFSITE(r) a system for i.v. therapy and shifts production to factories in
the Dominican Republic, Italy, Brazil and Pennsylvania
B.Braun opens a new dialysis center in Slovakia
B.Braun opens its first dialysis center in Lithuania

B.Braun

2007 Health Robotics (Bolzano, Italy) and B.Braun announce a global strategic alliance for the
development of interfacing compatibility between CytoCare (automated preparation of intravenous
admixtures) and B.Braun‘s Elastomeric Infusors and soft plastic bottles
B.Braun wins the 2007 Gold Medical Device Excellence Award (MDEA) for its PINNACLE
TPN Management System, a medical device that improves patient safety and compounding
efficiency
As a result of the competition “365 Orte im Land der Ideen“, B.Braun is awarded
“Ausgewählter Ort 2007“ by Deutsche Bank; B.Braun took part in the competition with its infusion
solutions production plant L.I.F.E. (Leading Infusion Factory Europe)
B.Braun is named a recipient of the 2007 Frost&Sullivan Medical Device Global
Excellence Award
Sepsis knowledge website is launched (www.sepsis.bbraun.de)
Acquisition of the renal dialysis and consumables business of Reading (UK)-
based BM Browne
B.Braun is planning to build and commission further six renal units in UK over the
coming year; it now employs more than 150 people in the UK and provides service to 620 NHS
patients in dialysis units in Bangor, Merthyr Tydfil, Newport, Cardiff, Kidderminster, Bristol and
Ipswich
B.Braun announces a 1.4bn Euro worldwide investment program; 50% of this
amount will be invested in Germany

B.Braun

2007 A new Avitum dialysis center is inaugurated in Sigishoara, Romania by the minister of health of
Romania, Eugen Nicolaescu; the center will be equipped with a maximum of beds and will initially
treat 24 patients; Avitum operates 3 dialysis centers in Romania with more than 250 patients
and plans to further expand during the next years
B.Braun is named “Category Leader“ in the KLAS Top 20 mid-year report card for smart
pump technology
B.Braun Medical launches the ONGUARD Contained Medication System with
TEVADAPTOR components manufactured by Teva Medical Ltd; the drug admixture and
delivery system provides hazard protection and passive needle stick prevention to nurses and
pharmacists for the reparation and administration of chemotherapeutics
Premier Purchasing Partners, LP, the healthcare purchasing unit of Premier, Inc.,
renewed its agreement considering B.Braun‘s line of safety iv catheters; the three-year contract
will become effective in October 2007 and will complement Premier‘s existing five-year agreement
encompassing all major B.Braun safe solutions
Announcement of a cooperation with Nipro; Nipro gains exclusive distributorship
rights in Japan for B.Braun‘s products for interventional cardiology and vascular grafts
Hygiene knowledge website is launched (www.hygiene.bbraun.de)

B.Braun

2007 The Czech antitrust office (UOHS) scraps a tender, which was won by B.Braun,
that the hospital in Ceske Budejovice launched for the supply of medical material worth almost
140m crowns (EUR5.8m (06/08))
2008 B.Braun will construct a 35m USD medical equipment plant in Vietnam in the northern province
of Ha Tay, Thanh Oai Industrial Complex; after the second phase of construction, the factory will
have an annual manufacturing capacity of 15m units
B.Braun publishes details on its worldwide investment plans concerning the
expansion of production and logistics facilities; about EUR 700m of EUR 1.4bn will be invested in
Germany, of which EUR 360m are invested in facilities in and around Melsungen; in Radeberg,
dialyser production capacity will be increased to 9m units annually in Melsungen, a new
dialysis machine production plant will be set up with an initial production volume of 10,000
units annually
B.Braun Medical Industries is investing RM450m (EUR 90m (06/08)) into the
expansion of its facility in Bayan Lepas Industrial Zone, Malaysia; production space for
intravenous standard solutions will be expanded and a new R&D center for intravenous access
products will be installed
B.Braun announces to set up standalone dialysis centers throughout India; in
about 300 B.Braun dialysis machines had been installed in India
B.Braun acquires 11,263 sq ft space at Avenue Business Park in Cardiff, South Wales,
UK, for a kidney dialysis unit

B.Braun

2008 In Jul., B.Braun informs that it has established a subsidiary in India including a plant for the
manufacture of cardiovascular equipments in Chennai; until 2010, total investments will add
up to EUR 16m
Acquisition of Gematek, a manufacturer of infusion solutions in Twer, Russia
In Jul., B.Braun receives three GHX market intelligence best in class awards for having
significant market share positions and/or growth for distributed products; B.Braun was among five
medical/surgical manufacturers in five market segments recognized by GHX: Hospital, Physician
Office, Long Term Care, Home Health Care and Treatment Centers (B.Braun is one of approx. 20
industry equity holders in GHX, a healthcare trading exchange)
In Jul., the European Investment Bank (EIB) lends B.Braun EUR 125m for the
expansion of its research infrastructure and the development of innovative pharmaceutical products
at the firm’s headquarters in Melsungen
In Jul., in an article titled “Medical Device Leasing in Clinics” Christian Braun of B.Braun
says that alternative financing strategies would increase especially for bigger devices such as
dialysis machines; this creates additional administrative expenditures for suppliers
In Jul., B.Braun announces the groundbreaking of its new LIFE nutrition plant for
clinical nutrition solutions; 270 employees (80 new) will work at the new plant; the investment
volume amounts to EUR 190m; two production lines for the filling of two- and three-
chamber bags will be installed
In Aug., B.Braun renews its agreement with Premier Purchasing Partners in the USA for
the supply of iv therapies and solutions; the supply agreement commenced in 2003

B.Braun

2008 In Aug., B.Braun and PEI enter into a joint venture in Ireland named “B.Braun Avitum
Ireland (BBAVI)“; PEI operates clinics in Kilkenny and Galway through its subsidiary “Wellstone“;
aim of the joint venture is to bring a new choice to the Irish renal care clinician in terms of
hemodialysis machines, consumables and customer support
In Sep., B.Braun USA introduces industry-first silver impregnated needle-free
luer access device (ULTRASITE® Ag Luer Access Device) for the reduction of potential catheter-
related bloodstream infections
In Oct., after eight years in office, Ludwig Georg Braun, the president of the German
Association of Chambers of Commerce and Industry, announces not to run for re-election in 2009
anymore
In Nov., B.Braun wins the BDU-Company Award 2008 for its innovative leadership and
its commitment to quality (BDU = German Federal Association of Management Consultants)
In Nov., B.Braun Avitum announces the finalisation of acquisition of dialysis clinics
in Lithuania and Latvia; B.Braun acquired the Dializes Centras Group, which consists of UAB
“Dializes Centras” (Lithuania) and its two subsidiaries – UAB “Kauno Dializes Centras” (Lithuania)
and SIA “Dializes Centrs” (Latvia); B.Braun Avitum Lithuania now operates eight dialysis
centers in the Baltic region with more than 200 patients
In Nov., UNICO, the purchasing syndicate of 13 university clinics, awards B.Braun
supplier of the year 2007
In Dec., B.Braun announces, that Central Admixture Pharmacy Services will introduce a
number of advances to its products an services, including enhanced dose labeling, extended
Beyond-Use-Dating (BUD) and American Society for Testing and Materials (ASTM) colour-coding for
its new anaesthesia syringe product line
B.Braun

2008 In Dec., the supervisory board appoints Dr. Hanns-Peter Knaebel as deputy member of the
managing board effective April 1, 2009; he will be responsible for the Aesculap division; Prof.
Michael Ungethüm will retire from the managing board at the end of March 2009 and
continue to support B.Braun in an advisory function
In Dec., at the American Society of Health-System Pharmacists (ASHP) midyear clinical
meeting and exhibition, B.Braun presents its Waste Weight Calculation Tool - an online program
that allows hospitals to analyse how much environmental waste they could reduce by using
B.Braun IV bags
2009 In Jan., B.Braun Medical Inc., USA launches a new web site exclusively devoted to products,
support services and educational information for home infusion therapy (HIT)
(http://www.hit.bbraunusa.com)
In Jan., B.Braun announces to expand operations in Penang, Malaysia by investing
about EUR 64.5m into its manufacturing facility at the Bayan Lepas Industrial Zone
In Feb., B.Braun establishes a subsidiary in Croatia; B.Braun Adria represents a
joint venture with its long standing partner, the Dzepina family
In Feb., B.Braun announces that it has been awarded a three-year contract by
Premier Purchasing Partners, Pennsylvania, US for both hemodialysis and continuous renal
replacement therapy; B.Braun has a long-standing relationship with Premier in other product
areas; adding renal products to B.Braun’s broad offering gives Premier members a more complete
solution to improve patient care

B.Braun

2009 In Feb., it is published that B.Braun Medical Inc. is planning to expand manufacturing at its
sites in Irvine and Westminster (manufacturing of drug, nutritional, and other
intravenous solutions) and to hire an additional 300 workers
In Mar., CRF, a leading research company in the area of employer branding has
identified B.Braun as the most attractive employer in Germany; B.Braun convinced in the
categories “work-life-balance“, “job safety“ and “corporate culture“
Open Text announces that B.Braun Melsungen AG will deploy a company-wide
enterprise content management solution based on the Open Text ECM Suite
In Mar., the city council of Tarnopol, Ukraine and B.Braun Avitum Poland sign a
cooperation for the establishment of a private dialysis center and the exchange of medical
and technical knowledge in dialysis as well as shared education and research in nephrology
In Mar., B.Braun reports financials for fiscal year 2008; the group revenue increased
by +6% to EUR 3.8bn; group income after tax decreased by -15% to EUR 185m; revenue of
B.Braun Avitum increased by +14.6% to EUR 403m; R&D investments increased by +12.1%
In May, B.Braun coins the term “Avitum Village” when talking about its EUR 82m
investment into dialysis machine and infusion pump manufacturing plant as well as a training
center (to increase the number of technical apprentices) at Melsungen; production is planned to
start in Q3 2010
In May, B.Braun introduces its new online clearance measurement tool Adimea
based on LDIAMON technology and its new xevonta dialysers with amembris
polyethersulfone membrane at the WCN in Milan

B.Braun

2009 In Jun., NxStage announces that its Medisystems in-center business has completed
development of the new Streamline blood tubing sets for use on the B.Braun Dialog and
Dialog+ dialysis systems in the US; the existing supply agreement will be expanded including
the new blood tubing; B.Braun provides sales, marketing and clinical support in the US
In Jun., the Medical Device & Diagnostics Industry magazine recognizes three medical
devices manufactured by B.Braun; B.Braun’s EXCEL and PAB IV containers represented major
advancements in environmental responsibility as the only PVC-free, DEHP-free containers available
with a full range of basic iv solutions; the Outlook Safety Infusion System represented a pioneering
innovation
In Jun., the German Association of Chambers of Industry and Commerce
implements a new committee for “Gesundheitswirtschaft” and elects Ludwig Georg Braun as
chairman
In Jul., B.Braun launches its new website
In Jul., B.Braun releases its new software KIK 4.0 for application in intensive care
units; the unique software allows to analyse i.v. regimen (combinations of intravenous
medication and parenteral nutrition) for incompatibilities before administration
In Aug., B.Braun is awarded “Surgery Center Market Supplier of the Year” in the USA
by McKesson’s medical-surgical business unit; award criteria include customer service excellence,
sales profitability, operational efficiency and delivery of customer value throughout the supply chain
In Sep., B.Braun launches its new product-focused German website including a
product quick-finder

B.Braun

2009 In Oct., it is announced that B.Braun will invest EUR 100m and expand its intravenous standard
solutions plant in Penang, Malaysia
In Oct., B.Braun announces that it has expanded a five-year agreement with
Amerinet Inc., a leading US healthcare group purchasing organization; B.Braun supplies
Amerinet members with i.v. pumps and solutions, needle-free products, clinical nutrition and drug
admixture and delivery services; the availability of PVC-free and DEHP-free i.v. solutions is
specifically emphasized
A new website informs specifically about B.Braun‘s service offering
(www.dienstleistungen.bbraun.de)
In Nov., B.Braun presents its new product Coroflex DEBLue, a hybrid system made
of a paclitaxel coated drug-eluting balloon (DEB) with a premounted bare metal stent which
represents an alternative to drug-eluting stents
Acquisition of 11 dialysis centers in India and 2 in Malaysia
2010 In Jan., B.Braun announces a new worldwide EUR 1.6bn investment program for the period
2011 to 2014; the company plans to construct a third L.I.F.E. factory in Melsungen, to renew
the location in Malaysia, to build a new infusion solutions factory in Indonesia and to
expand its sites in Brazil and Argentina; this investment program will be financed from the
company’s operating cash flow
In Jan., B.Braun US introduces oncology infusion therapy product WHIN Safe Huber
Needle; an implantable port access device that protects from needle stick injuries and expelled
blood and fluid (www.whinsafe.bbraunusa.com)

B.Braun

2010 Target software solution GmbH lists B.Braun as customer for its idea management software
In Mar., B.Braun Avitum is granted a seven year contract to operate two dialysis
clinics in Helsinki, Finland; each center will treat approximately 60 patients; operations in the
two centers will start on March 15, 2010 in the first and in Jan. 2011 in the second center
In Mar., it is announced that B.Braun India enters into a public private partnership
with the Government of Andhra Pradesh (AP) to operate 11 dialysis centers in medical
colleges and hospitals, which will be equipped with 111 hemodialysis machines; in total, 1,000
patients will be treated
In Mar., Dr. Hanns-Peter Knaebel is appointed full member of the Management Board
In Mar., B.Braun opens a Business School in England for the training of the
company‘s own staff including an apprenticeship scheme for young professionals, a sales
academy, management progression, professional development and an executive business academy
In Mar., B.Braun publishes its 2009 financials; corporate sales increased by +6.4% to
ÉUR 4,028m; sales of dialysis division Avitum increased by +4.4% to EUR 421m; unit sales of
machines decreased as a result of the financial and economic crisis particulary in Western Europe
and North America; due to positive developments in Peru and China, sales of machines (by
value) decreased only slightly; sales of dialysis disposables remained stable; in Germany,
sales increased above average
In Apr., it is published that already in Dec. 2009, B.Braun opened a dialysis clinic
with 10 machines in Harare, Zimbabwe

B.Braun

2010 In Apr., a local newspaper mentions that B.Braun establishes a dialysis machine manufacturing
capacity of 15,000 units annually at its new plant in Melsungen (a previous statement informed
about an "initial“ production volume of 10,000 units annually)
In Apr., launch of Adimea in the US for the spectroscopic measurement of molar
concentration of urinary excreted substances to determine dialysis effectiveness during treatment
In Apr., it is announced that B.Braun will invest EUR 4m in 2010 and EUR 2m in 2011 to
expand capacities at its newly acquired infusion solutions plant Helvetica Profarm SA in
Timisoara, Romania
In Apr., B.Braun receives marketing authorisation in the US for its Diacap HiFlo
2.3m polysulfone dialyser
2
In Jul., B.Braun starts using Twitter to distribute company news in German language
In Jul., B.Braun expands the production of infusion bags and opens a new
production line at its existing production site in Crissier, close by Lausanne, Switzerland; a second
floor with 4,000m² allows for potential further expansion; in the future, Crissier will serve as the
central manufacturing plant for multi-chamber infusion bags
In Sep., B.Braun CEO Ludwig Georg Braun is awarded “Deutscher
Gründerpreis”; he was honored for his achievement in terms of internationalization, innovation
and establishment of a corporate culture at B.Braun
In Oct., Redsense announces B.Braun as distributor for its business in the
Netherlands
In Oct., B.Braun wins third consecutive three-year contract from Premier, Inc. For
the delivery of safety IV catheters
B.Braun

2010 In Nov., B.Braun loses a lawsuit against Terumo Corp.; a jury decided that a 2007 patent of
B.Braun which was infringed byTerumo, is not valid; the non-valid patent covers a Braun invention
for a catheter device with a safety clip to prevent accidental needle sticks
In Dec., the supervisory board of B.Braun Melsungen AG appoints Heinz-Walter
Große as the new Chairman of the Board; he successes Ludwig Georg Braun who retires on
March 31st, 2011; Annette Beller and Mr. Otto Philipp Braun are appointed Deputy Members of the
Management Board; Caroll H. Neubauer‘s appointment to the management board is extended
through 2016
2011 In Feb., B.Braun officially opens a production site expansion in Timisoara, Romania; the new
facility is operational since early 2011 and was subject to a EUR 4m investment to reach a
capacity of 19m units of infusion solutions annually; it will serve as distribution hub in
South-East Europe; B.Braun intends to invest EUR 2m into upgrading production facilities and
further integration of B.Braun Pharmaceuticals SA into the B.Braun production sites network
worldwide
In Feb., B.Braun announces to spend EUR 50m to extend its production facility in
Glandorf, Germany; EUR 20m to built up a 11,000m² fully automated rack storage for 30,000
pallets; EUR 30m to build a new dialysis solution manufacturing line with a capacity of 37m
bags; current capacity amounts to 60m liter p.a.; manufacturing begin is planned in May 2011 and
completion is planned in Q1 2013
In Mar., B.Braun publishes its financials for 2010; corporate sales increased by 9.8
percent to EUR 4,422.8m; sales of dialysis division Avitum increased by 12.9 percent to EUR
474.8m

B.Braun

2011 In Apr., the change in the Management Board, which was agreed upon in December 2010, takes
place; Dr. Heinz-Walter Große succeeds Prof. Dr. h. c. Ludwig Georg Braun as Chairman of
the Management Board while remaining responsible for Human Resources and Legal
Affairs. Dr. Annette Beller succeeded Dr. Große as Chief Financial Office; Mr. Otto Philipp
Braun becomes a member of the Management Board and is responsible for the Iberian Peninsula
and Latin America.
In Apr., the new B.Braun CEO Große announces the strategic objective to increase
revenues from currently EUR 4.4bn to EUR 6bn in 2015; investments to achieve this will
add up to EUR 2.3bn until 2015
In Jun., the company announces to become partner of the German medical
practitioner portal medperts.de; the website aims to inform doctors on medical information and
serves as platform to exchange expertise and connect via the web; this objective is also reflected
in B.Braun’s company philosophy “Sharing Expertise”
In Jul., B.Braun announces to invest CHF 18m in the production site Escholzmatt
in Switzerland; CHF 10m are dedicated to increase production capacity for large syringes, CHF
3.5m to produce system Discofix and CHF 4.5m to start production of port systems for dialysis
bags

B.Braun

2011 In Jul., B.Braun acquires a patent which covers technology claims for enhanced communication
between medical devices and hospital information management systems through wireless
communication; the patent was issued in April 2011 and allows for greater connectivity options for
B.Braun’s Outlook Safety System and Space Infusion System smart pump
In Jul., B.Braun introduces the Plasmattm Futura Apheresis system onto the US market
as part of B.Braun’s H.E.L.P. Apheresis Therapy; it features a new state-of-the-art user interface
and does not require an on-site water treatment system
In Aug., B.Braun Serbia officially takes over B.Braun Hospital Care and Aesculap trading
operations; products will be marketed under the name B.Braun; the corporation’s name is B.Braun
Adria RSRB DOO
In Aug., launch of two YouTube channels (www.youtube.com/AesculapUSA and -
/AesculapImplant1) by Aesculap and Aesculap Implant Systems, LCC; the latter was established by
Aesculap in 2005; the channels will feature company videos on surgeries, patient testimonials and
product animation
In Aug., B.Braun announces to invest in a new training center in Melsungen for up to
200 technical apprentices; in June, B.Braun also purchased 4,300m 2 property to build a branch of
Aesculap Academies; scheduled begin of production is in 2012; the academy provides further
education for doctors, nurses and clinical managers

B.Braun

2011 In Aug., Terumo announces to expand the sale of its safety device Sureshield Surflo II for
intravenous catheters in South-East Asian markets after a Malaysian court ruled a non-infringement
of B.Braun’s patent in July 2011; B.Braun had already lost another lawsuit against Terumo on this
device in November 2010
In Sep., B.Braun lays cornerstone for a HUF 4bn (USD ~ 19m) expansion of its plant in northern
Hungary; investment will entail construction of 2,900-square-meter production hall and 2,200-
square-meter logistics warehouse; doubling production capacity and increase number of workers to
750 from current 650 expected; investment is planned to be completed in 2013
In Oct., German Chancellor Angela Merkel officially opens new B.Braun production plant in Viet
Nam; B.Braun invested EUR 32.6m in new IV set production facility in Viet Nam; increased
production from 35m to 100m units per year with long term output target of 200m
In Oct., FDA grants 510(k) clearance for B.Braun medical’s introcan safety®3 closed IV Catheter
which offers a passive safety needle shield
In Oct., B.Braun announces to invest EUR 38m in extension of the production plant by 65% in
Berlin; start of production planned at the end of 2013; investment creates at least 25 new
workspaces
In Nov., B.Braun Renal Therapies Division announced availability of 1100g Solcart B® Cartridge for
use with the Dialog+ Hemodialysis System; cartridge enables safe and efficient dispensing of
bicarbonate for extended therapies
In Nov., B.Braun wins Public Private Award 2011 for best business division 2010
In Nov., B.Braun is honoured with the demographic prize for being a good example how to cope
with demographic change

B.Braun

2012 In Jan., NxStage announces extended agreement with B.Braun for supply with its Streamline
blood tubing sets, MasterGuard and Buttonhole needles; agreement extended through 2014
In Jan., B.Braun acquiredsNutrichem which is specialized on products for special dietary
requirement; B.Braun desires to strengthen its business area of enteral nutrition and clinical
nutrition
In Feb., B.Braun announces cooperation with Lauer membrane water technology; B.Braun
takes over sale for Lauer’s dialysis water technology worldwide
In Mar., B.Braun publishes results of fiscal year 2011; sales EUR 4,609.4m (+4.2%); net income
EUR 255.7m (-7.8%); employees 43,676 (+5.7%); B.Braun continues its growth trend;
strongest contributors are Aesculap and Hospital Care Division
In Mar., B.Braun announces share purchase agreement between B.Braun Singapore PTE Ltd and
Ahlcon Parenterals (India) Ltd; B.Braun aquires 1,872,039 equity shares for Rs 460 each; equity
stake 26%
In Mar., B.Braun re-elects Dr. Meinrad Lugan as BVMed-Chairman; Lugan has been chairing BVMed
since April 2007
In Mar., B.Braun announces appointment of Dr. Annette Beller and Otto Philipp Braun as full board
members effective on April 01, 2012; Beller chairs Finance, Tax & Controlling department; Braun is
responsible for Iberian Peninsula and Latin America
In Apr., B.Braun Medical International in Spain acquires 60% of shares in Ventas Paraguayas a
distributor for B.Braun in Paraguay; the new company name will be B.Braun Medical SA Paraguay

B.Braun

2012 In Apr., B.Braun opens its distribution center in Melsungen to the public; the center has
room for 68,000 pallets and works daily on 4,000 delivery notes; almost 30% of B.Brauns revenue
of EUR 4.6bn is being distributed from Melsungen
In May, B.Braun underlines its growth ambitions by confirming the aim (communicated
by H.-W. Große in April 2011) to increase sales to EUR 6bn until 2015; in fiscal year 2011, profit
and income expectations were not met as sales increased only 4.2% to EUR 4.6bn and annual net
profit decreased 8.0% to EUR 256bn; with its 44,000 employees, B.Braun holds on to its medium-
term goal of 17-18% EBITDA by 2015, although last year EBITDA margin decreased by 0.9%-
points to 14.9%
In May it was announced that the upcoming board meeting will be held in B.Braun’s site in Penang,
Malaysia; this underlines the growth ambitions in the Asia-Pacific region for the upcoming years
In May, a new machine to produce urinary catheters arrives at B.Braun’s plant in Nogent, France
In May, B.Braun Aesculap Academy starts the first construction phase for a new biomedicine
park in Bochum, Germany; sale contract for the 4,300 square meter property was signed in June 2011;
total investment amount is EUR 16.5m; opening is planned for April 2013 after 14 months of construction

B.Braun

2012 In Jun., B.Braun informs about the situation at its production site in Mirandola, Italy, which was hit
by two earthquakes; delivery problems are expected with some products as great damages prohibit
entering the building and transport finished products and safety stock out of storage; affected
products: H.E.L.P. Plasmat Futura Kits cannot be delivered for about 4 -6 weeks, short-term
delivery problems may occur with Diapact CRRT Kits, concentrate bags are not deliverable at the
moment
In Jun., B.Braun announces that its HealthCare Journal is available as App for the Apple iPad free of
charge
In Jul., B.Braun is among top 25 “Best Companies to Work for” 2012 in India; improvement from
rank 71 in 2011 to 21 in 2012; 2nd rank in the healthcare sector
In Jul., it was announced that B.Braun supplies its customers in Paris by means of electric cars in
order to cut the environmental impact of its supply chain
In Aug., B.Braun opens on-site health clinic for its 1,200 employees at its Marcon Boulevard
production plant in Pennsylvania; the clinic is run by Walgreens and offers blood pressure and
cholesterol monitoring, taking lab samples, prescriptions and physical therapy
In Aug., B.Braun’s App of its HealthCare Journal is now available in Apple’s AppStore; only in
German language


Aun CFF 12 Final

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Aun CFF 12 Final

Uploaded by

Copyright:

Available Formats

Competitor Fact File

Status as of August 2012

Competitor Fact File

Strategic Coordination Office

International Strategic Development & Strategic Coordination Office © August, 2012

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Out Patient Market

* based in Tuttlingen, Germany

Strictly Confidential For internal Use Only

1) Effective stake 2) Companies with profit and loss transfer agreements

Strictly Confidential For internal Use Only

1) Effective stake 2) Companies with profit and loss transfer agreements

Source: B.Braun Annual Report 2011

Strictly Confidential For internal Use Only

In March 2012, Dr.

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Revenues Avitum 351 403 421 475 501 + 5.5

Thereof provider ~ 130 E ~152 E ~ 160 E ~ 194 E ~ 213 E + 30.0

R&D 116 130 139 155 180 + 16.1

Operating Profit 349 346 411 456 432 - 5.3

Cash Flow from 298 364 571 389 450 + 15.7

Cash Flow from - 357 - 467 - 443 - 557 - 548 + 1.6

Free Cash Flow - 59 - 103 176 - 168 - 98 + 41.7

Cash and Cash 41 53 49 34 45 + 32.4

Employees 35,810 38,460 39,500 41,666 43,676 + 4.8

2010 Operating profit margin:11.0% 2011 Operating profit margin:9.4 %

Strictly Confidential For internal Use Only

Total revenues 2011: EUR 4,609m

Corporate Corporate Corporate

Avitum Others Services Asia & Australia

Source: B.Braun Annual Report 2011

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Acute dialysis, therapeutic apheresis products:

• Apheresis: Plasmafilter, Precipitatefilter, Heparinadsorber,

Diapact CRRT Plasmat Futura

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

• "Avitum Village" Dialysis Machines and Infusion Pumps, Melsungen, Germany

Avitum Village in Melsungen, Germany

Strictly Confidential For internal Use Only

Continuous communication about investment programs:

B.Braun press release, March 2012:

B.Braun press release, April 2011:

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Strictly Confidential For internal Use Only

Dialog Dialog Advanced

Strictly Confidential For internal Use Only

• First automated system for LDL

Strictly Confidential For internal Use Only

Source: Marcus Klaschka, International Marketing,

Strictly Confidential For internal Use Only

Xevonta Lo series: Low-flux

At EDTA 2012 in Paris, B.Braun

Strictly Confidential For internal Use Only

Diacap HI PS series: High-flux